Список литературы

Поставить закладку

Johns L. E., Houlston R. S. A systematic review and meta-analysis of familial colorectal cancer risk // Am J Gastroenterol. ‒ 2001. ‒ T. 96, № 10. ‒ C. 2992-3003.
Tenesa A., Dunlop M. G. New insights into the aetiology of colorectal cancer from genome-wide association studies // Nat Rev Genet. ‒ 2009. ‒ T. 10, № 6. ‒ C. 353-8.
Huxley R. R., Ansary-Moghaddam A., Clifton P., Czernichow S., Parr C. L., Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence // Int J Cancer. ‒ 2009. ‒ T. 125, № 1. ‒ C. 171-80.
Rasool S., Kadla S. A., Rasool V., Ganai B. A. A comparative overview of general risk factors associated with the incidence of colorectal cancer // Tumour Biol. ‒ 2013. ‒ T. 34, № 5. ‒ C. 2469- 76.
Raskov H., Pommergaard H. C., Burcharth J., Rosenberg J. Colorectal carcinogenesis--update and perspectives // World J Gastroenterol. ‒ 2014. ‒ T. 20, № 48. ‒ C. 18151-64.
Каприн А., Старинский В., Петрова Г. Злокачественные новообразования в России (заболеваемость и смертность) // М.: ФГБУ «МНИОИ им. ПА Герцена» Минздрава России. ‒ 2017. ‒ T. 250.
Group M. S. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study // Radiology. ‒ 2007. ‒ T. 243, № 1. ‒ C. 132-9.
Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Rödel C., Cervantes A., Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. ‒ 2018.
Holland-Frei Cancer Medicine Cloth. / Bast Jr R. C., Croce C. M., Hait W. N., Hong W. K., Kufe D. W., Piccart-Gebart M., Pollock R. E., Weichselbaum R. R., Wang H., Holland J. F.: John Wiley & Sons, 2017.
The ASCRS textbook of colon and rectal surgery. / Steele S. R., Hull T. L., Read T. E., Saclarides J., Senagore A. J., Whitlow C. B.: Springer, 2016.
Malik S. S., Lythgoe M. P., McPhail M., Monahan K. J. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis // Familial cancer. ‒ 2018. ‒ T. 17, № 4. ‒ C. 557-564.
van Erp S. J., Leicher L. W., Hennink S. D., Ghorbanoghli Z., Breg S. A., Morreau H., Nielsen M., Hardwick J. C., Roukema J. A., Langers A. M. Identiﬁcation of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study // Scandinavian journal of gastroenterology. ‒ 2016. ‒ T. 51, № 10. ‒ C. 1227-1232.
Syngal S., Fox E. A., Eng C., Kolodner R. D., Garber J. E. Sensitivity and speciﬁcity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1 // J Med Genet. ‒ 2000. ‒ T. 37, № 9. ‒ C. 641-5.
Цуканов А. С., Шелыгин Ю. А., Ачкасов С. И., Фролов С. А., Кашников В. Н., Кузьминов А. М., Пикунов Д. Ю., Шубин В. П. Принципы диагностики и персонифицированного лечения наследственных форм колоректального рака // Вестник Российской академии медицинских наук. ‒ 2019. ‒ T. 74, № 2. ‒ C. 118-124.
Liu Z., Zhang Y., Niu Y., Li K., Liu X., Chen H., Gao C. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer // PLoS One. ‒ 2014. ‒ T. 9, № 8. ‒ C. e103910.
Tanaka A., Sadahiro S., Suzuki T., Okada K., Saito G. Comparisons of Rigid Proctoscopy, Flexible Colonoscopy, and Digital Rectal Examination for Determining the Localization of Rectal Cancers // Dis Colon Rectum. ‒ 2018. ‒ T. 61, № 2. ‒ C. 202-206.
Chong A., Shah J. N., Levine M. S., Rubesin S. E., Laufer I., Ginsberg G. G., Long W. B., Kochman M. L. Diagnostic yield of barium enema examination after incomplete colonoscopy // Radiology. ‒ 2002. ‒ T. 223, № 3. ‒ C. 620-4.
Pickhardt P. J., Hassan C., Halligan S., Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis // Radiology. ‒ 2011. ‒ T. 259, № 2. ‒ C. 393-405.
Kim J. H., Kim W. H., Kim T. I., Kim N. K., Lee K. Y., Kim M. J., Kim K. W. Incomplete colonoscopy in patients with occlusive colorectal cancer: usefulness of CT colonography according to tumor location // Yonsei Med J. ‒ 2007. ‒ T. 48, № 6. ‒ C. 934-41.
Neri E., Giusti P., Battolla L., Vagli P., Boraschi P., Lencioni R., Caramella D., Bartolozzi C. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy // Radiology. ‒ 2002. ‒ T. 223, № 3. ‒ C. 615-9.
Langevin J. M., Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study // Am J Surg. ‒ 1984. ‒ T. 147, № 3. ‒ C. 330-3.
Mulder S. A., Kranse R., Damhuis R. A., de Wilt J. H., Ouwendijk R. J., Kuipers E. J., van Leerdam M. E. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study // Cancer Epidemiol. ‒ 2011. ‒ T. 35, № 5. ‒ C. 442-7.
Martling A., Holm T., Bremmer S., Lindholm J., Cedermark B., Blomqvist L. Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer // Br J Surg. ‒ 2003. ‒ T. 90, № 11. ‒ C. 1422-8.
Algebally A. M., Mohey N., Szmigielski W., Yousef R. R., Kohla S. The value of high-resolution MRI technique in patients with rectal carcinoma: pre-operative assessment of mesorectal fascia involvement, circumferential resection margin and local staging // Pol J Radiol. ‒ 2015. ‒ T. 80. ‒ C. 115-21.
Norenberg D., Sommer W. H., Thasler W., D"Haese J., Rentsch M., Kolben T., Schreyer A., Rist C., Reiser M., Armbruster M. Structured Reporting of Rectal Magnetic Resonance Imaging in Suspected Primary Rectal Cancer: Potential Beneﬁts for Surgical Planning and Interdisciplinary Communication // Invest Radiol. ‒ 2017. ‒ T. 52, № 4. ‒ C. 232-239.
Battersby N. J., How P., Moran B., Stelzner S., West N. P., Branagan G., Strassburg J., Quirke P., Tekkis P., Pedersen B. G., Gudgeon M., Heald B., Brown G., Group M. I. S. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratiﬁcation Model: The MERCURY II Study // Ann Surg. ‒ 2016. ‒ T. 263, № 4. ‒ C. 751-60.
Sahni V. A., Silveira P. C., Sainani N. I., Khorasani R. Impact of a Structured Report Template on the Quality of MRI Reports for Rectal Cancer Staging // AJR Am J Roentgenol. ‒ 2015. ‒ T. 205, № 3. – C. 584-8.
Vliegen R. F., Beets G. L., von Meyenfeldt M. F., Kessels A. G., Lemaire E. E., van Engelshoven J. M., Beets-Tan R. G. Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful? // Radiology. ‒ 2005. ‒ T. 234, № 1. ‒ C. 179-88.
Floriani I., Torri V., Rulli E., Garavaglia D., Compagnoni A., Salvolini L., Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis // J Magn Reson Imaging. ‒ 2010. ‒ T. 31, № 1. ‒ C. 19-31.
Schmoll H. J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van de Velde C. J., Balmana J., Regula J., Nagtegaal I. D., Beets-Tan R. G., Arnold D., Ciardiello F., Hoff P., Kerr D., Kohne C. H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J. Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making // Ann Oncol. ‒ 2012. ‒ T. 23, № 10. ‒ C. 2479- 516.
Niekel M. C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment // Radiology. ‒ 2010. ‒ T. 257, № 3. ‒ C. 674-84.
Choi S. H., Kim S. Y., Park S. H., Kim K. W., Lee J. Y., Lee S. S., Lee M. G. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis // J Magn Reson Imaging. ‒ 2018. ‒ T. 47, № 5. ‒ C. 1237-1250.
Ko Y., Kim J., Park J. K.-H., Kim H., Cho J. Y., Kang S.-B., Ahn S., Lee K. J., Lee K. H. Limited detection of small (≤ 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection // PloS one. ‒ 2017. ‒ T. 12, № 12. ‒ C. e0189797.
Lazzaron A., Vieira M., Damin D. Should preoperative chest computed tomography be performed in all patients with colorectal cancer? // Colorectal Disease. ‒ 2015. ‒ T. 17, № 10. ‒ C. O184-O190.
Herrmann J., Lerman A., Sandhu N. P., Villarraga H. R., Mulvagh S. L., Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology // Mayo Clin Proc. ‒ 2014. – T. 89, № 9. ‒ C. 1287-306.
Starck M., Bohe M., Simanaitis M., Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers // Colorectal Dis. ‒ 2003. ‒ T. 5, № 3. ‒ C. 246-50.
Santoro G. A., Gizzi G., Pellegrini L., Battistella G., Di Falco G. The value of high-resolution three-dimensional endorectal ultrasonography in the management of submucosal invasive rectal tumors // Dis Colon Rectum. ‒ 2009. ‒ T. 52, № 11. ‒ C. 1837-43.
Zorcolo L., Fantola G., Cabras F., Marongiu L., D"Alia G., Casula G. Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic ﬁndings // Surg Endosc. ‒ 2009. ‒ T. 23, № 6. ‒ C. 1384- 9.
Roth E. S., Fetzer D. T., Barron B. J., Joseph U. A., Gayed I. W., Wan D. Q. Does colon cancer ever metastasize to bone ﬁrst? a temporal analysis of colorectal cancer progression // BMC cancer. ‒ 2009. ‒ T. 9, № 1. ‒ C. 274.
Augestad K. M., Bakaki P. M., Rose J., Crawshaw B. P., Lindsetmo R. O., Dorum L. M., Koroukian S. M., Delaney C. P. Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis // Cancer Epidemiol. ‒ 2015. ‒ T. 39, № 5. ‒ C. 734-44.
Daza J. F., Solis N. M., Parpia S., Gallinger S., Moulton C. A., Belley-Cote E. P., Levine M. N., Serrano P. E. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases // Eur J Surg Oncol. ‒ 2019. ‒ T. 45, № 8. ‒ C. 1341-1348.
Muntean V., Oniu T., Lungoci C., Fabian O., Munteanu D., Molnar G., Bintintan V. Staging laparoscopy in digestive cancers // J Gastrointestin Liver Dis. ‒ 2009. ‒ T. 18, № 4. ‒ C. 461-7.
De Marco M. F., Janssen-Heijnen M. L., van der Heijden L. H., Coebergh J. W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study // Eur J Cancer. ‒ 2000. – T. 36, № 1. ‒ C. 95-9.
Khattak M. A., Martin H., Davidson A., Phillips M. Role of ﬁrst-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials // Clin Colorectal Cancer. – 2015. ‒ T. 14, № 2. ‒ C. 81-90.
Pietrantonio F., Petrelli F., Coinu A., Di Bartolomeo M., Borgonovo K., Maggi C., Cabiddu M., Iacovelli R., Bossi I., Lonati V., Ghilardi M., de Braud F., Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta- analysis // Eur J Cancer. ‒ 2015. ‒ T. 51, № 5. ‒ C. 587-94.
Prasad V., Kaestner V., Mailankody S. Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deﬁcient solid cancers // JAMA oncology. ‒ 2018. ‒ T. 4, № 2. ‒ C. 157-158.
Therkildsen C., Bergmann T. K., Henrichsen-Schnack T., Ladelund S., Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis // Acta Oncol. ‒ 2014. ‒ T. 53, № 7. ‒ C. 852-64.
Jasperson K. W., Tuohy T. M., Neklason D. W., Burt R. W. Hereditary and familial colon cancer // Gastroenterology. ‒ 2010. ‒ T. 138, № 6. ‒ C. 2044-58.
Medina Pabon M. A., Babiker H. M. A Review Of Hereditary Colorectal Cancers // StatPearls. ‒ Treasure Island (FL), 2019.
Wada H., Shiozawa M., Katayama K., Okamoto N., Miyagi Y., Rino Y., Masuda M., Akaike M. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer // J Gastroenterol. ‒ 2015. ‒ T. 50, № 7. ‒ C. 727-34.
Beaton C., Twine C. P., Williams G. L., Radcliffe A. G. Systematic review and meta-analysis of histopathological factors inﬂuencing the risk of lymph node metastasis in early colorectal cancer // Colorectal Dis. ‒ 2013. ‒ T. 15, № 7. ‒ C. 788-97.
Siddiqui M. R. S., Simillis C., Bhoday J., Battersby N. J., Mok J., Rasheed S., Tekkis P., Abulaﬁ A. M., Brown G. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours // Eur J Cancer. ‒ 2018. ‒ T. 104. ‒ C. 47-61.
Guerra G. R., Kong C. H., Warrier S. K., Lynch A. C., Heriot A. G., Ngan S. Y. Primary squamous cell carcinoma of the rectum: An update and implications for treatment // World J Gastrointest Surg. ‒ 2016. ‒ T. 8, № 3. ‒ C. 252-65.
Vyas N., Ahmad S., Bhuiyan K., Catalano C., Alkhawam H., Sogomonian R., Nguyen J., Walﬁsh A., Aron J. Primary squamous cell carcinoma of the rectum: a case report and literature review // J Community Hosp Intern Med Perspect. ‒ 2016. ‒ T. 6, № 3. ‒ C. 31708.
Sturgeon J. D., Crane C. H., Krishnan S., Minsky B. D., Skibber J. M., Rodriguez-Bigas M. A., Chang G. J., You Y. N., Eng C., Das P. Deﬁnitive Chemoradiation for Squamous Cell Carcinoma of the Rectum // Am J Clin Oncol. ‒ 2017. ‒ T. 40, № 2. ‒ C. 163-166.
Babaei M., Jansen L., Balavarca Y., Sjovall A., Bos A., van de Velde T., Moreau M., Liberale G., Goncalves A. F., Bento M. J., Ulrich C. M., Schrotz-King P., Lemmens V., Glimelius B., Brenner H. Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes // Clin Colorectal Cancer. ‒ 2018. ‒ T. 17, № 1. ‒ C. e129-e142.
Abraha I., Aristei C., Palumbo I., Lupattelli M., Trastulli S., Cirocchi R., De Florio R., Valentini V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma // Cochrane Database Syst Rev. ‒ 2018. ‒ T. 10. ‒ C. CD002102.
Sager O., Dincoglan F., Demiral S., Uysal B., Gamsiz H., Dirican B., Beyzadeoglu M. A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases // Int J Surg Oncol. ‒ 2019. ‒ T. 2019. ‒ C. 5239042.
Kim M. J., Kim S. J., Park S. C., Kim D. Y., Park J. W., Ryoo S. B., Jeong S. Y., Park K. J., Oh H. K., Kim D. W., Kang S. B., Joo J. N., Oh J. H., Group S. E. C. Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta- analysis // Medicine (Baltimore). ‒ 2016. ‒ T. 95, № 47. ‒ C. e4925.
Liu Q., Shan Z., Luo D., Cai S., Li Q., Li X. Palliative beam radiotherapy offered real-world survival beneﬁt to metastatic rectal cancer: A large US population-based and propensity score- matched study // J Cancer. ‒ 2019. ‒ T. 10, № 5. ‒ C. 1216-1225.
De Caluwe L., Van Nieuwenhove Y., Ceelen W. P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer // Cochrane Database Syst Rev. ‒ 2013.10.1002/14651858.CD006041.pub3 № 2. ‒ C. CD006041.
De Caluwé L., Van Nieuwenhove Y., Ceelen W. P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer // Cochrane database of systematic reviews. ‒ 2013. № 2.
Latkauskas T., Pauzas H., Gineikiene I., Janciauskiene R., Juozaityte E., Saladzinskas Z., Tamelis A., Pavalkis D. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery // Colorectal Dis. ‒ 2012. ‒ T. 14, № 3. ‒ C. 294-8.
Hofheinz R. D., Wenz F., Post S., Matzdorff A., Laechelt S., Hartmann J. T., Muller L., Link H., Moehler M., Kettner E., Fritz E., Hieber U., Lindemann H. W., Grunewald M., Kremers S., Constantin C., Hipp M., Hartung G., Gencer D., Kienle P., Burkholder I., Hochhaus A. Chemoradiotherapy with capecitabine versus ﬂuorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial // Lancet Oncol. ‒ 2012. ‒ T. 13, № 6. ‒ C. 579-88.
O"Connell M. J., Martenson J. A., Wieand H. S., Krook J. E., Macdonald J. S., Haller D. G., Mayer R. J., Gunderson L. L., Rich T. A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion ﬂuorouracil with radiation therapy after curative surgery // N Engl J Med. ‒ 1994. ‒ T. 331, № 8. ‒ C. 502-7.
McCarthy K., Pearson K., Fulton R., Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer // Cochrane Database Syst Rev. ‒ 2012. ‒ T. 12. ‒ C. CD008368.
Ngan S. Y., Burmeister B., Fisher R. J., Solomon M., Goldstein D., Joseph D., Ackland S. P., Schache D., McClure B., McLachlan S. A., McKendrick J., Leong T., Hartopeanu C., Zalcberg J., Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04 // J Clin Oncol. ‒ 2012. ‒ T. 30, № 31. ‒ C. 3827-33.
Du D., Su Z., Wang D., Liu W., Wei Z. Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis // Clin Colorectal Cancer. ‒ 2018. ‒ T. 17, № 1. ‒ C. 13-24.
Petrelli F., Sgroi G., Sarti E., Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies // Ann Surg. ‒ 2016. ‒ T. 263, № 3. ‒ C. 458-64.
Lefevre J. H., Mineur L., Kotti S., Rullier E., Rouanet P., de Chaisemartin C., Meunier B., Mehrdad J., Cotte E., Desrame J., Karoui M., Benoist S., Kirzin S., Berger A., Panis Y., Piessen G., Saudemont A., Prudhomme M., Peschaud F., Dubois A., Loriau J., Tuech J. J., Meurette G., Lupinacci R., Goasgen N., Parc Y., Simon T., Tiret E. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6) // J Clin Oncol. ‒ 2016. ‒ T. 34, № 31. ‒ C. 3773-3780.
Marco M. R., Zhou L., Patil S., Marcet J. E., Varma M. G., Oommen S., Cataldo P. A., Hunt S. R., Kumar A., Herzig D. O., Fichera A., Polite B. N., Hyman N. H., Ternent C. A., Stamos M. J., Pigazzi A., Dietz D., Yakunina Y., Pelossof R., Garcia-Aguilar J., Timing of Rectal Cancer Response to Chemoradiation C. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial // Dis Colon Rectum. ‒ 2018. ‒ T. 61, № 10. ‒ C. 1146-1155.
Kim S. Y., Joo J., Kim T. W., Hong Y. S., Kim J. E., Hwang I. G., Kim B. G., Lee K. W., Kim J. W., Oh H. S., Ahn J. B., Zang D. Y., Kim D. Y., Oh J. H., Baek J. Y. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03 // Int J Radiat Oncol Biol Phys. – 2018. ‒ T. 101, № 4. ‒ C. 889-899.
Liang H. Q., Dong Z. Y., Liu Z. J., Luo J., Zeng Q., Liao P. Y., Wu D. H. Efﬁcacy and safety of consolidation chemotherapy during the resting period in patients with local advanced rectal cancer // Oncol Lett. ‒ 2019. ‒ T. 17, № 2. ‒ C. 1655-1663.
Pettersson D., Cedermark B., Holm T., Radu C., Pahlman L., Glimelius B., Martling A. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer // Br J Surg. ‒ 2010. ‒ T. 97, № 4. ‒ C. 580-7.
van der Valk M. J. M., Hilling D. E., Bastiaannet E., Meershoek-Klein Kranenbarg E., Beets G. L., Figueiredo N. L., Habr-Gama A., Perez R. O., Renehan A. G., van de Velde C. J. H., Consortium I. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study // Lancet. ‒ 2018. ‒ T. 391, № 10139. ‒ C. 2537-2545.
Dossa F., Chesney T. R., Acuna S. A., Baxter N. N. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis // Lancet Gastroenterol Hepatol. ‒ 2017. ‒ T. 2, № 7. ‒ C. 501- 513.
Cercek A., Roxburgh C. S. D., Strombom P., Smith J. J., Temple L. K. F., Nash G. M., Guillem J. G., Paty P. B., Yaeger R., Stadler Z. K., Seier K., Gonen M., Segal N. H., Reidy D. L., Varghese A., Shia J., Vakiani E., Wu A. J., Crane C. H., Gollub M. J., Garcia-Aguilar J., Saltz L. B., Weiser M. R. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer // JAMA Oncol. ‒ 2018. ‒ T. 4, № 6. – C. e180071.
Zhang J., Hu H., Cai Y., Chen D., Xiao J., Ling J., Deng Y. Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials // Book Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials / EditorAmerican Society of Clinical Oncology, 2018.
Mathis K. L., Nelson H., Pemberton J. H., Haddock M. G., Gunderson L. L. Unresectable colorectal cancer can be cured with multimodality therapy // Annals of surgery. ‒ 2008. ‒ T. 248, № 4. ‒ C. 592-598.
Minsky B. D., Cohen A. M., Kemeny N., Enker W. E., Kelsen D. P., Saltz L., Frankel J. The efﬁcacy of preoperative 5-ﬂuorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer // Cancer. ‒ 1993. ‒ T. 71, № 11. ‒ C. 3486-92.
Minsky B. D., Cohen A. M., Enker W. E., Saltz L., Guillem J. G., Paty P. B., Kelsen D. P., Kemeny N., Ilson D., Bass J., Conti J. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer // Int J Radiat Oncol Biol Phys. ‒ 1997. ‒ T. 37, № 2. – C. 289-95.
van der Pas M. H., Haglind E., Cuesta M. A., Furst A., Lacy A. M., Hop W. C., Bonjer H. J., Group C. O. c. L. o. O. R. I. S. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial // Lancet Oncol. ‒ 2013. ‒ T. 14, № 3. ‒ C. 210-8.
Jeong S. Y., Park J. W., Nam B. H., Kim S., Kang S. B., Lim S. B., Choi H. S., Kim D. W., Chang H. J., Kim D. Y., Jung K. H., Kim T. Y., Kang G. H., Chie E. K., Kim S. Y., Sohn D. K., Kim D. H., Kim J. S., Lee H. S., Kim J. H., Oh J. H. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non- inferiority, randomised controlled trial // Lancet Oncol. ‒ 2014. ‒ T. 15, № 7. ‒ C. 767-74.
Green B. L., Marshall H. C., Collinson F., Quirke P., Guillou P., Jayne D. G., Brown J. M. Long- term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer // Br J Surg. ‒ 2013. ‒ T. 100, № 1. ‒ C. 75- 82.
Schwenk W., Haase O., Neudecker J., Muller J. M. Short term beneﬁts for laparoscopic colorectal resection // Cochrane Database Syst Rev. ‒ 2005.10.1002/14651858.CD003145.pub2 № 3. ‒ C. CD003145.
Breukink S., Pierie J., Wiggers T. Laparoscopic versus open total mesorectal excision for rectal cancer // Cochrane Database Syst Rev. ‒ 2006.10.1002/14651858.CD005200.pub2 № 4. ‒ C. CD005200.
Ribas Y., Hotouras A., Wexner S. D., D"Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes // Colorectal Dis. ‒ 2016. ‒ T. 18, № 1. ‒ C. 9-12.
Chude G. G., Rayate N. V., Patris V., Koshariya M., Jagad R., Kawamoto J., Lygidakis N. J. Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study // Hepatogastroenterology. ‒ 2008. ‒ T. 55, № 86-87. ‒ C. 1562-7.
Гордеев С., Иванов В., Расулов А., Барсуков Ю., Ткачев С., Сураева Ю., Черных М., Кузьмичев Д., Козак Е., Малихов А. ХИМИОЛУЧЕВАЯ ТЕРАПИЯ ОСЛОЖНЕННОГО МЕСТНОРАСПРОСТРАНЕННОГО И РЕЦИДИВНОГО РАКА ПРЯМОМ КИШКИ // Медицинская радиология и радиационная безопасность. ‒ 2016. ‒ T. 61, № 6. ‒ C. 57-63.
Nascimbeni R., Nivatvongs S., Larson D. R., Burgart L. J. Long-term survival after local excision for T1 carcinoma of the rectum // Dis Colon Rectum. ‒ 2004. ‒ T. 47, № 11. ‒ C. 1773-9.
Sgourakis G., Lanitis S., Gockel I., Kontovounisios C., Karaliotas C., Tsiftsi K., Tsiamis A., Karaliotas C. C. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes // Am Surg. ‒ 2011. ‒ T. 77, № 6. ‒ C. 761-72.
Doornebosch P. G., Tollenaar R. A., De Graaf E. J. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justiﬁed? A systematic review // Acta Oncol. ‒ 2009. ‒ T. 48, № 3. ‒ C. 343-53.
Taylor F. G., Quirke P., Heald R. J., Moran B., Blomqvist L., Swift I., Sebag-Monteﬁore D. J., Tekkis P., Brown G., group M. s. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study // Ann Surg. ‒ 2011. ‒ T. 253, № 4. ‒ C. 711-9.
Cho S. H., Choi G. S., Kim G. C., Seo A. N., Kim H. J., Kim W. H., Shin K. M., Lee S. M., Ryeom H., Kim S. H. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis // Medicine (Baltimore). – 2017. ‒ T. 96, № 12. ‒ C. e6362.
Richardson B., Preskitt J., Lichliter W., Peschka S., Carmack S., de Prisco G., Fleshman J. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? // Am J Surg. ‒ 2016. ‒ T. 211, № 1. ‒ C. 46-52.
Allard M. A., Adam R., Giuliante F., Lapointe R., Hubert C., Ijzermans J. N. M., Mirza D. F., Elias D., Laurent C., Gruenberger T., Poston G., Letoublon C., Isoniemi H., Lucidi V., Popescu I., Figueras J. Long-term outcomes of patients with 10 or more colorectal liver metastases // Br J Cancer. ‒ 2017. ‒ T. 117, № 5. ‒ C. 604-611.
Adam R., Wicherts D. A., de Haas R. J., Ciacio O., Lévi F., Paule B., Ducreux M., Azoulay D., Bismuth H., Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure // J Clin Oncol. ‒ 2009. ‒ T. 27, № 11. ‒ C. 1829-1835.
Wang J., Luo L., Wang D., Guo B., Li J., Yang Z., Tang D. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis // J Cell Biochem. – 2018. ‒ T. 119, № 2. ‒ C. 1521-1537.
Brandi G., De Lorenzo S., Nannini M., Curti S., Ottone M., Dall"Olio F. G., Barbera M. A., Pantaleo M. A., Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis // World J Gastroenterol. ‒ 2016. ‒ T. 22, № 2. ‒ C. 519-33.
Modest D. P., Martens U. M., Riera-Knorrenschild J., Greeve J., Florschutz A., Wessendorf S., Ettrich T., Kanzler S., Norenberg D., Ricke J., Seidensticker M., Held S., Buechner-Steudel P., Atzpodien J., Heinemann V., Seufferlein T., Tannapfel A., Reinacher-Schick A. C., Geissler M. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) // J Clin Oncol. ‒ 2019.10.1200/JCO.19.01340. ‒ C. JCO1901340.
Федянин М., Трякин А., Тюляндин С. Потенциальные предикторы эффективности анти- EGFR-терапии при метастатическом раке толстой кишки // Онкологическая колопроктология. ‒ 2013. № 2.
Cetinkaya E., Dogrul A. B., Tirnaksiz M. B. Role of self expandable stents in management of colorectal cancers // World J Gastrointest Oncol. ‒ 2016. ‒ T. 8, № 1. ‒ C. 113-20.
Nielsen M. B., Laurberg S., Holm T. Current management of locally recurrent rectal cancer // Colorectal Dis. ‒ 2011. ‒ T. 13, № 7. ‒ C. 732-42.
Rahbari N. N., Ulrich A. B., Bruckner T., Munter M., Nickles A., Contin P., Lofﬂer T., Reissfelder C., Koch M., Buchler M. W., Weitz J. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? // Ann Surg. ‒ 2011. ‒ T. 253, № 3. ‒ C. 522-33.
Lee J. H., Kim D. Y., Kim S. Y., Park J. W., Choi H. S., Oh J. H., Chang H. J., Kim T. H., Park S. W. Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer // Radiat Oncol. ‒ 2011. – T. 6. ‒ C. 51.
Tanis P. J., Doeksen A., van Lanschot J. J. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review // Can J Surg. ‒ 2013. ‒ T. 56, № 2. ‒ C. 135-44.
Bird T. G., Ngan S. Y., Chu J., Kroon R., Lynch A. C., Heriot A. G. Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent // Int J Colorectal Dis. ‒ 2018. ‒ T. 33, № 4. ‒ C. 393-401.
Watanabe J., Shoji H., Hamaguchi T., Miyamoto T., Hirano H., Iwasa S., Honma Y., Takashima A., Kato K., Ito Y., Itami J., Kanemitsu Y., Boku N. Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients // In Vivo. ‒ 2019. ‒ T. 33, № 4. ‒ C. 1363-1368.
Yu S. K., Bhangu A., Tait D. M., Tekkis P., Wotherspoon A., Brown G. Chemoradiotherapy response in recurrent rectal cancer // Cancer Med. ‒ 2014. ‒ T. 3, № 1. ‒ C. 111-7.
Guren M. G., Undseth C., Rekstad B. L., Braendengen M., Dueland S., Spindler K. L., Glynne- Jones R., Tveit K. M. Reirradiation of locally recurrent rectal cancer: a systematic review // Radiother Oncol. ‒ 2014. ‒ T. 113, № 2. ‒ C. 151-7.
Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer // Int J Colorectal Dis. ‒ 2015. ‒ T. 30, № 4. ‒ C. 447-57.
Andre T., Colin P., Louvet C., Gamelin E., Bouche O., Achille E., Colbert N., Boaziz C., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Billiau V., Buyse M., Gramont A., Groupe d"Etude et de Recherche Clinique en Oncologie R. Randomized adjuvant study comparing two schemes of 5-ﬂuorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d"Etude et de Recherche Clinique en Oncologie Radiotherapies // Semin Oncol. ‒ 2001. ‒ T. 28, № 1 Suppl 1. ‒ C. 35-40.
Breugom A. J., van Gijn W., Muller E. W., Berglund A., van den Broek C. B., Fokstuen T., Gelderblom H., Kapiteijn E., Leer J. W., Marijnen C. A., Martijn H., Meershoek-Klein Kranenbarg E., Nagtegaal I. D., Pahlman L., Punt C. J., Putter H., Roodvoets A. G., Rutten H. J., Steup W. H., Glimelius B., van de Velde C. J., Cooperative Investigators of Dutch Colorectal Cancer G., Nordic Gastrointestinal Tumour Adjuvant Therapy G. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial // Ann Oncol. ‒ 2015. ‒ T. 26, № 4. ‒ C. 696-701.
Guo Y., Xiong B. H., Zhang T., Cheng Y., Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis // Cancer Invest. ‒ 2016. ‒ T. 34, № 2. ‒ C. 94-104.
Kato T., Nagata N., Fujii M., Takemoto H., Kondo K., Okuyama Y., Tominaga H., Sakamoto J., Mishima H. Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study // Anticancer Res. ‒ 2011. ‒ T. 31, № 12. ‒ C. 4657-64.
Andre T., Quinaux E., Louvet C., Colin P., Gamelin E., Bouche O., Achille E., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Lledo G., Raoul Y., Debrix I., Buyse M., de Gramont A. Phase III study comparing a semimonthly with a monthly regimen of ﬂuorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: ﬁnal results of GERCOR C96.1 // J Clin Oncol. ‒ 2007. ‒ T. 25, № 24. ‒ C. 3732-8.
Mizushima T., Ikeda M., Kato T., Ikeda A., Nishimura J., Hata T., Matsuda C., Satoh T., Mori M., Doki Y. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open- label, single-arm phase II study // BMC Cancer. ‒ 2019. ‒ T. 19, № 1. ‒ C. 929.
Федянин М., Трякин А., Тюляндин С. Адъювантная химиотерапия после химиолучевого лечения рака прямой кишки // Онкологическая колопроктология. ‒ 2014. № 2.
Seymour M. T., Maughan T. S., Ledermann J. A., Topham C., James R., Gwyther S. J., Smith D. B., Shepherd S., Maraveyas A., Ferry D. R., Meade A. M., Thompson L., Grifﬁths G. O., Parmar M. K., Stephens R. J., Investigators F. T., National Cancer Research Institute Colorectal Clinical Studies G. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial // Lancet. ‒ 2007. ‒ T. 370, № 9582. ‒ C. 143-152.
Cunningham D., Sirohi B., Pluzanska A., Utracka-Hutka B., Zaluski J., Glynne-Jones R., Koralewski P., Bridgewater J., Mainwaring P., Wasan H. Two different ﬁrst-line 5-ﬂuorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer // Annals of oncology. ‒ 2008. ‒ T. 20, № 2. ‒ C. 244-250.
Ackland S. P., Jones M., Tu D., Simes J., Yuen J., Sargeant A. M., Dhillon H., Goldberg R. M., Abdi E., Shepherd L., Moore M. J. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer // Br J Cancer. ‒ 2005. ‒ T. 93, № 11. ‒ C. 1236-43.
Baraniskin A., Buchberger B., Pox C., Graeven U., Holch J. W., Schmiegel W., Heinemann V. Efﬁcacy of bevacizumab in ﬁrst-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis // Eur J Cancer. ‒ 2019. ‒ T. 106. ‒ C. 37-44.
Rosa B., de Jesus J. P., de Mello E. L., Cesar D., Correia M. M. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta- analysis // Ecancermedicalscience. ‒ 2015. ‒ T. 9. ‒ C. 582.
Le D. T., Uram J. N., Wang H., Bartlett B. R., Kemberling H., Eyring A. D., Skora A. D., Luber B. S., Azad N. S., Laheru D., Biedrzycki B., Donehower R. C., Zaheer A., Fisher G. A., Crocenzi T. S., Lee J. J., Duffy S. M., Goldberg R. M., de la Chapelle A., Koshiji M., Bhaijee F., Huebner T., Hruban R. H., Wood L. D., Cuka N., Pardoll D. M., Papadopoulos N., Kinzler K. W., Zhou S., Cornish T. C., Taube J. M., Anders R. A., Eshleman J. R., Vogelstein B., Diaz L. A., Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deﬁciency // N Engl J Med. ‒ 2015. ‒ T. 372, № 26. ‒ C. 2509-20.
Overman M. J., McDermott R., Leach J. L., Lonardi S., Lenz H. J., Morse M. A., Desai J., Hill A., Axelson M., Moss R. A., Goldberg M. V., Cao Z. A., Ledeine J. M., Maglinte G. A., Kopetz S., Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deﬁcient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study // Lancet Oncol. ‒ 2017. ‒ T. 18, № 9. ‒ C. 1182-1191.
Overman M. J., Lonardi S., Wong K. Y. M., Lenz H. J., Gelsomino F., Aglietta M., Morse M. A., Van Cutsem E., McDermott R., Hill A., Sawyer M. B., Hendlisz A., Neyns B., Svrcek M., Moss R. A., Ledeine J. M., Cao Z. A., Kamble S., Kopetz S., Andre T. Durable Clinical Beneﬁt With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deﬁcient/Microsatellite Instability-High Metastatic Colorectal Cancer // J Clin Oncol. ‒ 2018. ‒ T. 36, № 8. ‒ C. 773-779.
Le D. T., Kim T. W., Van Cutsem E., Geva R., Jager D., Hara H., Burge M., O"Neil B., Kavan P., Yoshino T., Guimbaud R., Taniguchi H., Elez E., Al-Batran S. E., Boland P. M., Crocenzi T., Atreya C. E., Cui Y., Dai T., Marinello P., Diaz L. A., Jr., Andre T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deﬁcient Metastatic Colorectal Cancer: KEYNOTE-164 // J Clin Oncol. ‒ 2019.10.1200/JCO.19.02107. ‒ C. JCO1902107.
Cremolini C., Loupakis F., Antoniotti C., Lupi C., Sensi E., Lonardi S., Mezi S., Tomasello G., Ronzoni M., Zaniboni A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as ﬁrst- line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study // The Lancet Oncology. ‒ 2015. ‒ T. 16, № 13. ‒ C. 1306-1315.
Pratyaksha W., Valentina P., Ben V., Peter K., Evaristo M., Mark J. G., Curca R.-O. D., Meinolf K., Bridgewater J. A., Mihailov A. C. VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aﬂibercept activity // ANNALS OF ONCOLOGY. ‒ 2017. ‒ T. 28.
Kopetz S., McDonough S. L., Morris V. K., Lenz H.-J., Magliocco A. M., Atreya C. E., Diaz L. A., Allegra C. J., Wang S. E., Lieu C. H. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406) // Book Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406) / EditorAmerican Society of Clinical Oncology, 2017.
Corcoran R. B., Andre T., Atreya C. E., Schellens J. H. M., Yoshino T., Bendell J. C., Hollebecque A., McRee A. J., Siena S., Middleton G., Muro K., Gordon M. S., Tabernero J., Yaeger R., O"Dwyer P. J., Humblet Y., De Vos F., Jung A. S., Brase J. C., Jaeger S., Bettinger S., Mookerjee B., Rangwala F., Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer // Cancer Discov. ‒ 2018. ‒ T. 8, № 4. ‒ C. 428-443.
Vieitez J. M., Carrasco J., Esteban E., Fra J., Alvarez E., Muniz I., Sala M., Buesa J. M., Jimenez Lacave A. Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage // Am J Clin Oncol. ‒ 2003. ‒ T. 26, № 2. ‒ C. 107-11.
Bayraktar B., Ozemir I. A., Kefeli U., Demiral G., Sagiroğlu J., Bayraktar O., Adali G., Ozcelik A., Tortum O. B. Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study // World Journal of Gastroenterology: WJG. ‒ 2015. ‒ T. 21, № 31. ‒ C. 9373.
Cameron M. G., Kersten C., Vistad I., Fosså S., Guren M. G. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer–a systematic review // Acta Oncologica. ‒ 2014. ‒ T. 53, № 2. ‒ C. 164-173.
Costi R., Leonardi F., Zanoni D., Violi V., Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist // World Journal of Gastroenterology: WJG. – 2014. ‒ T. 20, № 24. ‒ C. 7602.
Silver J. K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes // American journal of physical medicine & rehabilitation. ‒ 2013. ‒ T. 92, № 8. ‒ C. 715- 727.
Greer N. L., Gunnar W. P., Dahm P., Lee A. E., MacDonald R., Shaukat A., Sultan S., Wilt T. J. Enhanced Recovery Protocols for Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis // Dis Colon Rectum. ‒ 2018. ‒ T. 61, № 9. ‒ C. 1108-1118.
Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery // Int J Surg. ‒ 2017. ‒ T. 39. ‒ C. 156-162.
Gillis C., Li C., Lee L., Awasthi R., Augustin B., Gamsa A., Liberman A. S., Stein B., Charlebois P., Feldman L. S., Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer // Anesthesiology. ‒ 2014. ‒ T. 121, № 5. ‒ C. 937-47.
Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological prehabilitation before cancer surgery: a systematic review // Annals of surgical oncology. ‒ 2015. ‒ T. 22, № 13. ‒ C. 4117-4123.
Li P., Fang F., Cai J. X., Tang D., Li Q. G., Wang D. R. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis // World J Gastroenterol. ‒ 2013. ‒ T. 19, № 47. ‒ C. 9119-26.
Wren S. M., Martin M., Yoon J. K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward // J Am Coll Surg. ‒ 2010. ‒ T. 210, № 4. ‒ C. 491-5.
de Almeida E. P. M., de Almeida J. P., Landoni G., Galas F., Fukushima J. T., Fominskiy E., de Brito C. M. M., Cavichio L. B. L., de Almeida L. A. A., Ribeiro U., Jr., Osawa E. A., Diz M. P., Cecatto R. B., Battistella L. R., Hajjar L. A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial // Br J Anaesth. ‒ 2017. ‒ T. 119, № 5. ‒ C. 900-907.
Visser W. S., Te Riele W. W., Boerma D., van Ramshorst B., van Westreenen H. L. Pelvic ﬂoor rehabilitation to improve functional outcome after a low anterior resection: a systematic review // Ann Coloproctol. ‒ 2014. ‒ T. 30, № 3. ‒ C. 109-14.
Efthimiadis C., Basdanis G., Zatagias A., Tzeveleki I., Kosmidis C., Karamanlis E., Harlaftis N. Manometric and clinical evaluation of patients after low anterior resection for rectal cancer // Techniques in coloproctology. ‒ 2004. ‒ T. 8, № 1. ‒ C. s205-s207.
Finnane A., Janda M., Hayes S. C. Review of the evidence of lymphedema treatment effect // Am J Phys Med Rehabil. ‒ 2015. ‒ T. 94, № 6. ‒ C. 483-98.
Cheville A. L., Kollasch J., Vandenberg J., Shen T., Grothey A., Gamble G., Basford J. R. A home- based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial // J Pain Symptom Manage. ‒ 2013. ‒ T. 45, № 5. ‒ C. 811-21.
Jeon J., Sato K., Niedzwiecki D., Ye X., Saltz L. B., Mayer R. J., Mowat R. B., Whittom R., Hantel A., Benson A., Wigler D. S., Atienza D., Messino M., Kindler H., Venook A., Fuchs C. S., Meyerhardt J. A. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance // Clin Colorectal Cancer. ‒ 2013. ‒ T. 12, № 4. ‒ C. 233-8.
Mosher C. E., Winger J. G., Given B. A., Helft P. R., O"Neil B. H. Mental health outcomes during colorectal cancer survivorship: a review of the literature // Psychooncology. ‒ 2016. ‒ T. 25, № 11. ‒ C. 1261-1270.
Mustian K. M., Alfano C. M., Heckler C., Kleckner A. S., Kleckner I. R., Leach C. R., Mohr D., Palesh O. G., Peppone L. J., Piper B. F., Scarpato J., Smith T., Sprod L. K., Miller S. M. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta- analysis // JAMA Oncol. ‒ 2017. ‒ T. 3, № 7. ‒ C. 961-968.
Kinkead B., Schettler P. J., Larson E. R., Carroll D., Sharenko M., Nettles J., Edwards S. A., Miller A. H., Torres M. A., Dunlop B. W., Rakofsky J. J., Rapaport M. H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial // Cancer. ‒ 2018. ‒ T. 124, № 3. – C. 546-554.
Bensadoun R. J., Nair R. G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy // Photomed Laser Surg. ‒ 2015. ‒ T. 33, № 10. ‒ C. 487-91.
Pita-Fernandez S., Alhayek-Ai M., Gonzalez-Martin C., Lopez-Calvino B., Seoane-Pillado T., Pertega-Diaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis // Ann Oncol. ‒ 2015. – T. 26, № 4. ‒ C. 644-56.
Jeffery M., Hickey B. E., Hider P. N. Follow-up strategies for patients treated for non- metastatic colorectal cancer // Cochrane Database Syst Rev. ‒ 2007.10.1002/14651858.CD002200.pub2 № 1. ‒ C. CD002200.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница